| Code | CSB-MP008645HU(F3) |
| Abbreviation | Recombinant Human FGFR2 protein, partial (Active) |
| MSDS | |
| Size | $138 |
| Order now | |
| Image |
|
| Have Questions? | Leave a Message or Start an on-line Chat |
FGFR2 dysregulation drives oncogenesis in gastric, breast, and endometrial cancers, making this receptor a critical target for therapeutic antibody development and small-molecule inhibitor screening. This mammalian-expressed construct spanning residues 22–378 of isoform 3 captures the complete extracellular ligand-binding domain, ensuring native glycosylation patterns that preserve conformational epitopes essential for antibody epitope mapping and blocking antibody screening. Functional ELISA validation demonstrates specific antibody binding with an EC50 of 1.066–1.203 ng/mL, confirming that the protein retains its native structure and supports quantitative ligand-receptor interaction assays, competitive inhibition studies, and affinity characterization by surface plasmon resonance or biolayer interferometry. Dual chromatographic analysis confirms >95% purity by both SDS-PAGE and SEC-HPLC, and endotoxin levels below 1.0 EU/μg satisfy the contamination thresholds typical for cell-based assays in drug discovery workflows.
There are currently no reviews for this product.